Table 3.
Regimen course | Reference | Study length | Number of patients | Eligbility | Response | OS | PFS | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First line | Recurrence/progression | CR (%) | PR (%) | MR/SD (%) | PD (%) | year | % | year | % | ||||
CBP-VCR | Packer et al 1993 | NA | 60 | yes | yes | 2 | 37 | 50 | 11 | NA | NA | ||
Packer et al 1997 | 1989–1993 | 78 | yes | yes | 5 | 28 | 60 | 6 | 3 | 97 | 3 | 68 | |
Demaerel et al 2002 | NA | 9 | yes | no | 0 | 55 | 45 | 0 | NA | NA | |||
Gnekow et al 2004 | 1996–2004 | 123 | yes | no | 2 | 6 | 76 | 7 | 5 | 87 | 5 | 61 | |
Ronghe M et al 2010 | 1996–2006 | 16 | yes | yes | 6 | 50 | 38 | 6 | NA | NA | |||
Ater et al 2012 | 1997–2000 | 137 | yes | yes | CR/PR: 35 | 32 | 33 | 5 | 86 | 5 | 39 | ||
| |||||||||||||
CBP/VP16 CPP/VCR lomustine/PC/VCR |
Bruggers et al 2007 | NA | 10 | yes | yes | 20 | 10 | 70 | 0 | NA | NA | ||
| |||||||||||||
PC/CBP VP16/CisP VCR/CCP |
Laithier et al 2003 | 1990–1998 | 85 | no | yes | 0 | 42 | 45 | 13 | 5 | 89 | 5 | 34 |
| |||||||||||||
CBP/VP16 | Castello et al 1995 | NA | 13 | yes | no | 8 | 0 | 70 | 22 | NA | NA | ||
| |||||||||||||
CBP/tamoxifene | Walther et al 2011 | NA | 13 | yes | no | 0 | 15 | 69 | 15 | 3 | 69 | 3 | 47 |
| |||||||||||||
CBP/vinblastine | Jakackl et al 2011 | 2006–2008 | 26 | yes | yes | 0 | 5 | 81 | 14 | NA | NA | ||
| |||||||||||||
CBP or Ibroplatine | Friedman et al 1992 | 1986–1990 | 12 | yes | yes | 0 | 0 | 75 | 25 | NA | NA | ||
| |||||||||||||
CisP/VCR | Massimino 2002 | 1991–2000 | 34 | yes | no | 3 | 32 | 65 | 0 | 3 | 100 | 3 | 78 |
Massimino 2010 | 2001–2007 | 37 | yes | no | 0 | 47 | 20 | 33 | 3 | 97 | 3 | 65 | |
| |||||||||||||
CBP | Moghrabl et al 1993 | NA | 6 | no | yes | 0 | 0 | 100 | 0 | NA | NA | ||
Aquino et al 1999 | 1992–1996 | 12 | no | yes | 0 | 33 | 50 | 17 | 3 | 83 | NA | ||
Gururangan et al 2002 | 1993–2000 | 81 | no | yes | 2 | 21 | 82 | 15 | 3 | 84 | 3 | 64 | |
| |||||||||||||
CisP | Hsu et al 2008 | 1992–2007 | 16 | no | yes | 0 | 25 | 31 | 44 | 5 | 94 | 5 | 56 |
| |||||||||||||
oxaliplatin | Beaty et al 2010 | 2004–2006 | 9 | no | yes | 0 | 0 | 38 | 62 | NA | NA | ||
| |||||||||||||
CisP/VCR | Sawamura et al 2009 | 1992–2008 | 15 | no | yes | 7 | 53 | 40 | 0 | NA | NA | ||
| |||||||||||||
VP16-VCR | Pons et al 1992 | NA | 20 | yes | yes | 0 | 0 | 71 | 29 | NA | NA | ||
| |||||||||||||
VCR/VP16/CPP/5-FU | Lee et al 2006 | 1999–2004 | 13 | no | yes | 8 | 38 | 23 | 31 | 6 | 100 | 6 | 67 |
| |||||||||||||
TMZ | Nicholson et al 2007 | 1998–1999 | 22 | no | yes | 0 | 5 | 95 | 0 | NA | NA | ||
Gururangan et al 2007 | 1999–2005 | 30 | no | yes | 0 | 10 | 43 | 47 | 4 | 71 | 4 | 17 | |
Khaw et al 2007 | 1999–2005 | 13 | no | yes | 15 | 23 | 23 | 38 | NA | 3 | 57 | ||
Bartels et al 2011 | 2000–2006 | 28 | no | yes | NA | NA | NA | NA | 2 | 71 | NA | ||
| |||||||||||||
TPDCV | Prados et al 1997 | 1984–1992 | 42 | yes | yes | 0 | 36 | 59 | 5 | 5 | 78 | NA | |
Mishra et al 2010 | 1984–1992 | 33 | yes | yes | 0 | NA | NA | 76 | 15 | 71 | 15 | 23 | |
| |||||||||||||
TPCV | Lancaster et al 2003 | NA | 10 | no | yes | NA | NA | 78 | NA | NA | NA | ||
Ater et al 2012 | 1997–2000 | 137 | yes | yes | CR/PR: 30 | 36 | 34 | 5 | 87 | 5 | 52 | ||
| |||||||||||||
BCNU/VCR/MTX-IT | Sumer et al 1978 | NA | 6 | NA | NA | NA | NA | 50 | NA | NA | NA | ||
| |||||||||||||
vinblastin | Lafaye-Cousin et al 2005 | NA | 9 | no | yes | 11 | 56 | 22 | 11 | NA | NA | ||
Bouffet et al 2012 | 2002–2009 | 51 | no | yes | 2 | 34 | 38 | 26 | 5 | 93 | 5 | 43 | |
| |||||||||||||
CPP | Kadota et al 1999 | 1996–1997 | 15 | no | yes | 7 | 0 | 57 | 36 | NA | NA | ||
| |||||||||||||
CBP/VCR VCR/VP16 TPCV vinblastine |
Scheinemann et al 2011 | 1985–2009 | 38 | no | yes | NA | NA | NA | NA | 5 | 86 | ; | 37 |
| |||||||||||||
bevacizumab/irinotecan | Packer et al 2009 | 2006–2008 | 10 | no | yes | 11 | 44 | 45 | 0 | NA | NA | ||
Coucec et al 2012 | 2007–2010 | 11 | no | yes | 0 | 63 | 0 | 37 | NA | NA | |||
| |||||||||||||
nimotuzumab | Saurez et al 2009 | 2005–2007 | 4 | no | yes | 0 | 0 | 50 | 50 | NA | NA | ||
| |||||||||||||
erlotinib/rapamycin | Yalon et al 2013 | 2007–2010 | 21 | no | yes | 0 | 6 | 35 | 59 | NA | NA | ||
| |||||||||||||
everolimus | Krueger et al 2010 | 2009–2010 | 28 | no | yes | 0 | 75 | 25 | 0 | NA | NA |
CBP: carboplatin, VCR: vincristine, VP16: etoposide, CPP: cyclophosphamide, PC: procarbazine, CisP: cisplatin, 5-FU: 5-fluorouracile, TMZ: temozolomide, TPDCV: five-drug regimen consisting of 6- thioguanine, procarbazine, dibromodulcitol, 1-(2-chloro- ethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine, TPCV: thioguanine, procarbazine, lomustine, and vincristine, BCNU: carmustine, MTX-IT: intrathecal injection of methotrexate, CR: complete response, PR: partial response, MR/SD: minor response/stable disease, PD: progressive disease, OS: overall survival, PFS: progression free survival